MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank 

Rhea-AI Summary

MindMaze Therapeutics (RLFTF) announced on March 19, 2026 that Baader Bank has initiated equity research coverage with a Buy recommendation and a CHF 1.80 target price.

According to the company, this new coverage complements existing research from Edison Group, which values the company at CHF 3.56 per share.

Positive

• Baader Bank initiated coverage with a Buy recommendation
• New analyst coverage may increase visibility and liquidity for RLFTF shares

Negative

• Target price divergence: Baader CHF 1.80 vs Edison CHF 3.56

Market Context

This announcement adds another supportive data point, with Baader Bank initiating coverage with a Bu...

Analysis

This announcement adds another supportive data point, with Baader Bank initiating coverage with a Buy rating and CHF 1.80 target, complementing Edison’s CHF 3.56 valuation. It follows a period of major change, including a business combination that increased the share count to 152,602,044 and coincided with a 61.34% decline. Earlier, positive clinical results and a reimbursement-focused Swiss program of CHF 11.2 million underpinned the growth narrative. Investors may monitor how future clinical, reimbursement, and integration milestones influence sentiment relative to these benchmarks.

Key Figures

Baader target price: CHF 1.80 per share Edison valuation: CHF 3.56 per share SwissNeuroRehab funding: CHF 11.2 million +5 more

8 metrics

Baader target price CHF 1.80 per share Initiation of coverage with Buy recommendation

Edison valuation CHF 3.56 per share Existing research coverage valuation

SwissNeuroRehab funding CHF 11.2 million Innosuisse-backed Swiss flagship reimbursement program

Completed clinical studies 27+ studies Evidence base for AI-driven neurorehabilitation

Regulatory clearances 11 clearances Global approvals supporting reimbursement strategy

Data volume 1.2 billion data points/month Neurotechnology data engine processing capacity

New shares issued 140,000,000 shares Business combination with NeuroX

Shares outstanding 152,602,044 shares Post-combination share count excluding treasury shares

Historical Context

4 past events · Latest: Dec 23 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 23	Reimbursement strategy	Positive	+12.6%	Global reimbursement push and Swiss-backed flagship program announcement.
Dec 15	Business combination close	Neutral	-61.3%	Completion of NeuroX combination and listing as MindMaze Therapeutics.
Nov 14	Deal approval	Positive	-7.3%	Shareholder approval of NeuroX business combination and capital increase.
Oct 29	Clinical study result	Positive	+0.2%	Pivotal bioequivalence study success for RLF-OD032 vs KUVAN Powder.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News has produced mixed reactions: strategic and clinical positives sometimes aligned with gains but large structural changes saw sharp drawdowns.

Recent Company History

Over the last few months, the company moved through major strategic and clinical milestones. On Oct 29, 2025, positive pivotal bioequivalence data for RLF-OD032 led to a modest 0.16% gain. Shareholders approved the NeuroX combination on Nov 14, 2025, yet the stock fell 7.3%. Completion of the business combination on Dec 15, 2025 coincided with a sharp 61.34% drop after issuing 140,000,000 new shares. A global reimbursement strategy update on Dec 23, 2025 then saw a positive 12.57% reaction. Today’s new analyst coverage comes against this backdrop of volatile responses to corporate developments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.

Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company's FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.

For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: MindMaze Therapeutics Holding SA

View the original press release on ACCESS Newswire

FAQ

What did MindMaze Therapeutics (RLFTF) announce on March 19, 2026?

They announced that Baader Bank initiated equity research coverage with a Buy recommendation. According to the company, Baader set a CHF 1.80 target and said this complements Edison Group coverage valuing the stock at CHF 3.56.

What is Baader Bank's recommendation and target price for RLFTF?

Baader Bank gave a Buy recommendation with a CHF 1.80 target price. According to the company, this is the specific price target published at the initiation of coverage on March 19, 2026.

How does Baader Bank's CHF 1.80 target compare to Edison's valuation for RLFTF?

Baader's CHF 1.80 target is notably lower than Edison's CHF 3.56 valuation. According to the company, both coverage reports now sit side-by-side, showing a material difference in analyst views.

Could Baader Bank's coverage affect MindMaze Therapeutics (RLFTF) stock trading?

New analyst coverage can influence trading by increasing visibility and trading interest. According to the company, Baader's initiation with a Buy and a published target provides a new reference point for investors evaluating RLFTF.

Does the announcement change MindMaze Therapeutics' guidance or financials for RLFTF?

No financial guidance or earnings figures were updated in this announcement; it only concerns analyst coverage. According to the company, the release reports initiation of coverage and respective target prices, not financial results.